- $102.63m
- $56.66m
- $28.70m
- 26
- 24
- 50
- 24
Annual balance sheet for Vaxart, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 127 | 166 | 95.7 | 39.7 | 51.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.334 | 0.071 | 0.02 | 3.01 | 12 |
Prepaid Expenses | |||||
Total Current Assets | 129 | 169 | 99.5 | 45.5 | 68.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8.32 | 19.8 | 41.3 | 36.6 | 29.1 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 153 | 221 | 154 | 91.8 | 166 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.8 | 10.8 | 17.9 | 13.7 | 90.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 29.2 | 33.6 | 43.3 | 34 | 107 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 123 | 188 | 111 | 57.8 | 58.9 |
Total Liabilities & Shareholders' Equity | 153 | 221 | 154 | 91.8 | 166 |
Total Common Shares Outstanding |